You are here

P&T News

April 29

First authorized test from commercial lab in U.S.
Combo treatment with lenalidomide and dexamethasone extends progression-free survival
Topoisomerase 1 inhibitors may blunt inflammatory storms

April 28

Medicare EHR incentive system will be phased out
Guidance emphasizes individualized treatment

April 27

Product overcomes patent-infringement lawsuit
Hospitals, insurers, and businesses prod drug-makers

April 26

Nonprofit group issues safety score update
Approval decision expected by May 26
Treatment demonstrates superior improvement in lung function versus mono-components and placebo
Therapy improves overall survival, progression-free survival, and objective response rate in phase 3 trial

Pages